BRAF and neoplasm: As a permanently activated kinase, mutated BRAF V600E can phosphorylate its downstream targets, such as MEK and ERK, and is associated with aggressive features, such as lymph node involvement, large tumor masses, or extrathyroid metastases, leading to a poor prognosis [65].